Earnings call
Narayana Hrudayalaya Q4 FY25 earnings call: Narayana Hrudayalaya Ltd. considers 40 hospitals in 10 years reasonable
By DalalOS Data Desk. Assembled by software from the company's transcript. Not reviewed by a person.
Transcript filed .
The company considers 40 hospitals in 10 years reasonable. The company plans to create chemotherapy centers outside hospitals in retail locations, partnering with doctors and real estate people who provide space; its first centers are coming up in Gurgaon in about a 5,000 sq. ft. space. Integrated care had a loss of INR 65 crores and cash burn in FY25. The company changed its contract in the Jammu region, Katra region, reducing bed numbers by 370 odd beds this quarter. The company expects to incur about INR 300 crores of regular capex in FY26 for replacement, maintenance and new capacities inside existing facilities.
The numbers management gave
Results
- Integrated care had a loss of INR 65 crores and cash burn in FY25.
Show source
For FY25, like you said, INR 65 crores is the loss which we have, cash burn that we have taken in Integrated care.
- The company reduced bed capacity by around 398 beds in FY23, by 112 beds in FY24, and by 160 beds this year.
Show source
It decreased by around 398 beds in FY23, in FY24 by 112 beds, and this year also 160 beds.
- The company consistently gets a yield of around INR 24 to 25 crores of other income from cash parked in its investments and current books.
Show source
So, on a consistent basis, we are getting a yield of around INR 24 to 25 crores of other income.
- India business EBITDA margins improved quarter-on-quarter with manpower costs improving by around 2% and other expenses by 1% overall, while realizations increased from the previous quarter to the current quarter.
Show source
R. Venkatesh: So, one is, if you look at the quarter-on-quarter, we have had improvements on the manpower costs by around 2% and also improvement in the other expenses by 1% on an overall.
- In Bangalore and Calcutta, international patient volume dipped more than 60%, but growth was sustained at 11% because domestic business grew by 15% to 16%.
Show source
But in spite of that, we've been able to sustain a growth of 11%, only because the domestic has gone up by 15% to 16%.
- The company operates at reasonable occupancy of 60 to 65%, while focusing on throughputs and efficiencies.
Show source
So, though we hover around… our reasonable occupancy between 60 to 65%, those are the numbers within which we do it.
Show 12 more statements
Results
- The company is in a near break-even situation in the Mumbai facility and is neither losing money nor adding financially.
Show source
We aren't losing money, but we aren't really adding financially.
- The company says patients prefer private and semi-private beds over general ward beds, contributing to its margins after transformation programs in major flagship units.
Show source
But when it comes to our differentiation between a ward to a semi-private and private, what we have done is, because of the recent transformation programs which we have done in the major units i.e. the flagship units, we have tried to do more of private, semi- private beds from the general ward beds, and we've realized that the patients are actually preferring more of these private beds than general ward beds, which has actually been a contributor to our margins.
- Slow payouts in the March quarter, mainly from ECHS and RGHS, impacted Narayana Hrudayalaya Ltd.'s DSO and left its working capital days higher than usual.
Show source
But there was a slowness in the payout, mainly payers like ECHS and RGHS, and that kind of impacted the DSO for the quarter.
- A marginal dip in Narayana Hrudayalaya Ltd.'s revenue share from cardiac sciences has come only because of fewer Bangladesh patients at the Health City hospital.
Show source
Some of this marginal dip which has come is only because of the Bangladesh patients in the Health City hospital, which has got the work coming down.
- The company has seen a reasonable upward trend in Bangladesh patients in the last few months. Replaced by a later filing.
Show source
But we've seen a reasonable upward trend in the last few months.
Money and capital
- The company expects to incur about INR 300 crores of regular capex in FY26 for replacement, maintenance and new capacities inside existing facilities.
Show source
For the FY26, there are two parts to the Capex, one is the regular capex that we incur, which is about INR 300 crores, which is on replacement, maintenance and new capacities that we are creating inside our existing facility.
- The company expects to spend approximately INR 450 crores on greenfield and brownfield capacity in FY26, subject to construction progress and some variability.
Show source
So, that is approximately INR 450 crores that we will spend in these new capacities.
- The company has gross debt above INR 2,000 crores.
Show source
Nishant Singh: See, the gross debt is obviously above INR 2,000 crores.
- The company had cash of around INR 1,600 crores on its balance sheet.
Show source
But if you look at the cash, we also have a very large cash corpus sitting in the balance sheet of around INR 1,600 crores.
- The company will continue with 80% debt for project finance loans, which are 15-25 years loans.
Show source
So those loans, we will continue with that 80% debt.
- Dividend policy is linked entirely to monetizing the Cayman cash reserve in a more tax efficient manner.
Show source
So, our dividend policy is linked entirely around being able to monetize the Cayman cash reserve and do it in a more tax efficient manner.
- The company raises debt for expansion. Replaced by a later filing.
Show source
Raising debt is for expansion.
What it expects ahead
What management expects
- The company considers 40 hospitals in 10 years reasonable.
Show source
Viren Shetty: 40 hospitals in 10 years seems reasonable.
- The 20-25% oncology growth and around 20% orthopedics growth may not be a stable state, as they are temporary effects of adding orthopedics as a single unit in the Health City and oncology and making investments in Shimoga and a few other cities.
Show source
Viren Shetty: No, it may not be a stable state.
- The company does not expect its cardiac business to ever go below 25-30%.
Show source
But I don't see the cardiac business ever going below 25-30%.
- Interest cost can be assumed to be around 8%, coming down because of T-bill movements on overall borrowing for India; the rate for Cayman can be taken as around 6 to 6.25%.
Show source
You can assume my interest cost of around 8%, which is actually coming down because of the movements in the T-bill on our overall borrowing for India and for the Cayman, you can take a rate of around 6 to 6.25%.
- The company does not see Cayman revenue going significantly below its current sustainable level for a sustained period.
Show source
Yeah, we don't see it going below this significantly for a sustained period of time for any reason.
- The company will prioritize tapping into a bigger revenue base in Cayman over improving margins beyond current levels.
Show source
Anesh Shetty: So, definitely beyond the point where we are, it doesn't make much sense to focus on improving margins at the expense of not tapping into a bigger revenue base.
Show 3 more statements
What management expects
- The company expects losses in Integrated care to grow in the current year because of its clinic portfolio expansion plan.
Show source
So, it won't stagnate at this level, the losses will grow.
- The company says improved throughput, higher order procedures, better payer mix, better bed mix, continuing to provide higher order care, and integrated care are drivers of its organic growth.
Show source
Sandhya J: So, from an organic growth point of view, I guess it is the same that we have explained earlier, which is, improved throughput, higher order procedures, better payer mix, better bed mix, being able to continue to keep providing higher order care, and also integrated care is helping.
- The company will never reconsider medical tourism in the American market.
Show source
No, we will never make that mistake again.
What it is building and selling
Projects and capacity
- The company plans to create chemotherapy centers outside hospitals in retail locations, partnering with doctors and real estate people who provide space; its first centers are coming up in Gurgaon in about a 5,000 sq. ft. space.
Show source
The size we're not yet finalized our first centers coming up in Gurgaon.
- The India business has a projected capex spend of around INR 425 crores for FY26.
Show source
For FY26, the projected spend is around INR 425 crores.
- Construction of the first phase at Rajarhat has started after all approval processes; the commissioning will take at least 30 months from now, with the first phase of around 350 beds expected to be functional near FY28.
Show source
So, mostly it will be functional somewhere near FY28 when it comes to Rajarhat at the first phase of around 350 beds. ‘28, I think.
- The company has projected 1,100 beds in total at Rajarhat, but is focused first on getting 350 beds off the ground and will take up the remainder as that capacity becomes full.
Show source
Viren Shetty: That's been projected.
Demand and pricing
- Pure price increases are very low single-digit numbers to cover inflation.
Show source
When it comes to pricing, pure price increase is very low single-digit numbers, just to cover up the inflations.
Segments
- The company changed its contract in the Jammu region, Katra region, reducing bed numbers by 370 odd beds this quarter.
Show source
Nishant Singh: See, this quarter the reason is, we have changed our contract in the Jammu region, Katra region, so that's why the number of beds has come down by 370 odd beds.
Show 4 more statements
Segments
- Cardiac sciences account for around 30-34% of Narayana Hrudayalaya Ltd.'s overall revenue.
Show source
Still, around 30-34% of the overall revenue comes from cardiac sciences.
- The company upgraded general ward capacity to private and semi-private capacity as part of a reorganization.
Show source
Sandhya J: Some reorganization we have done in terms of general ward capacity being upgraded to private and semi-private.
Deals and partners
- The company did not continue a few partnerships in Bellary and other locations before.
Show source
And for the other quarters, we have discussed that we did not continue few of our partnerships, Bellary and other locations before.
- The company is working with the Trust on levers to expedite its long recovery journey in Mumbai, with discussions at various stages.
Show source
It is a long journey for us in terms of recovery, and we are working with the Trust in terms of levers that can enable us to expedite that.
Risks, rules and outside factors
Outside factors
- 19 to 20% of Narayana Hrudayalaya Ltd.'s revenue comes from government payors.
Show source
The reason being that we have a certain exposure to government payors, as you are aware, 19 to 20% of our revenue comes from government payors.
Everything else said on the call
Group structure
- The company clarified to regulators in both markets that it had no intention of pursuing or making any offer or investment in Spire Healthcare.
Show source
So, Gagan, as soon as there was that information in the media, we issued a clarification to the regulators in both markets that we had no intention of pursuing or making any offer or investment in Spire Healthcare.
Other
- Overall Google rating across its facilities is between 4.8 and 4.9.
Show source
Sandhya J: If you look at our overall Google rating across the country, it is one of the highest, hovering between 4.8 and 4.9 across all our facilities.
What the company said on its earnings call, taken from its own transcript. Not advice.
Questions and answers
This transcript does not separate questions and answers, so they are not listed here.
Questions about this call
- When was the Narayana Hrudayalaya Q4 FY25 earnings call transcript filed?
- Narayana Hrudayalaya filed the transcript with the exchange on 2 Jun 2025. This page is built from that transcript.
- What does this page list?
- 40 statements from the transcript across 10 topics, 23 of them with a figure. Each statement is shown with the transcript sentence it came from.
- Are the analysts' questions included?
- No. This transcript does not separate the questions from the answers, so they are not listed. The statements by topic still cover what management said.
- Who wrote this page?
- DalalOS Data Desk. Assembled by software from the company's transcript. Not reviewed by a person. How it is made, and what it leaves out, is on the method page linked from the byline.